CD4 and myeloid sarcoma: Additionally, Herich et al. demonstrated that CD4+ TEM expressing high levels of CCR5 and GZMK are involved in CNS immune surveillance in healthy individuals, but that this subset was dominant in peripheral blood mononuclear cells of MS patients, and that natalizumab (anti-α4-integrin) treatment significantly decreased these cells [193].